Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-28T16:25:11.175Z Has data issue: false hasContentIssue false
  • English
  • Français

Desirable Immunologic Characteristics for the Development of an Ideal Vaccine

Published online by Cambridge University Press:  14 October 2009

Gordon Ada
Gordon Ada
Affiliation:
Australian National University
Get access Rights & Permissions [Opens in a new window]

Abstract

The efficacy of vaccines for prophylactic use is a function of the immune response elicited by activated lymphocytes. Based on the current understanding of these responses, their induction, and the most effective ways to obtain long-lived immunity, a novel protocol for the vaccination of children against seven childhood diseases, involving only two visits for vaccine administration, is proposed.

Type
Special Section: Vaccines and Public Health: Assessing Technologies and Public Policies
Information
International Journal of Technology Assessment in Health Care , Volume 10 , Issue 1 , Winter 1994 , pp. 71 - 80
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Ada, G. L.The immune response to antigens: The immunological principles of vaccination. Lancet, 1990, 335, 523–26.CrossRefGoogle ScholarPubMed
2.Ada, G. L.The ideal vaccine. World Journal of Microbiology and Biotechnology, 1991, 7, 105–09.CrossRefGoogle ScholarPubMed
3.Ada, G. L. Vaccines. In E. Paul, W. (ed.), Fundamental immunology, 3rd ed.New York: Raven Press, 1993, 1309–52.Google Scholar
4.Aldovini, A., & Young, R. A.Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature, 1991, 351, 479–82.CrossRefGoogle ScholarPubMed
5.Berkner, K. L.Expression of heterologous sequences in adenoviral vectors. Current Topics in Microbiology and Immunology, 1992, 158, 39–66.Google ScholarPubMed
6.Binns, M. M., & Smith, G. L. (eds.), Recombinant poxviruses. Boca Raton, FL: CRC Press, 1992.Google Scholar
7.Cadoz, M., Srady, A., Meigner, B., et al. Immunization with canarypox expressing rabies glycoprotein. Lancet, 1992, 339, 1429–32.CrossRefGoogle ScholarPubMed
8.Davis, A. R., Nayak, D. P., Veda, M., et al. Immune response to human influenza virus hemagglutinin expressed in E. coli. Gene, 1983, 21, 273–84.Google ScholarPubMed
9.Egea, E., Iglesias, A., Salazar, M., et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. Journal of Experimental Medicine, 1991, 173, 531–38.CrossRefGoogle ScholarPubMed
10.Eichelberger, M. C., Wang, M., Alan, W., et al. Influenza virus RNA in the lung and lymphoid tissue of immunologically intact and CD4-depleted mice. Journal of General Virology, 1991, 72, 1694–98.CrossRefGoogle ScholarPubMed
11.Gray, D., & Matzinger, P.T cell memory is short-lived in the absence of antigen. Journal of Experimental Medicine, 1991, 174, 969–74.CrossRefGoogle ScholarPubMed
12.Hill, A. B., Lobigs, M., Blanden, R. V., et al. The cellular immune response to flaviviruses. In B. Thomas, D. (ed.), Virus and the immune response. New York: Marcel Dekker, 1993, 363–88.Google Scholar
13.Mandel, T. E., Phipps, R. P., Abbot, A., & Tew, J. G.The follicular dendritic cell: Long term antigen retention during immunity. Immunological Reviews, 1980, 53, 29–59.CrossRefGoogle ScholarPubMed
14.McGhee, J. R., Mestecky, J., Dertzbaugh, M. T., et al. The mucosal immune system: From fundamental concepts to vaccine development. Vaccine, 1992, 10, 76–88.CrossRefGoogle ScholarPubMed
15.Morrison, J., Elvin, J., Latron, F., et al. Identification of the nonamer peptide from influenza: A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. European Journal of Immunology, 1992, 22, 903–07.CrossRefGoogle ScholarPubMed
16.Mossman, T. R., & Coffman, R.Two types of mouse helper T cell clones: Implications for immune regulation. Immunology Today, 1987, 8, 227–33.Google Scholar
17.Schodel, F.Prospects for oral vaccination using recombinant bacteria expressing viral epitopes. Advances in Virus Research, 1992, 41, 409–46.CrossRefGoogle ScholarPubMed
18.Stover, C. K., de la Cruz, V. F., Fuerst, T. R., et al. New use of BCG for recombinant vaccines. Nature, 1991, 351, 456–60.CrossRefGoogle ScholarPubMed
19.Tartaglia, J., Perkus, M. E., Taylor, J., et al. NYVAC, a highly attenuated strain of vaccinia virus. Virology, 1992, 188, 217–32.CrossRefGoogle ScholarPubMed
20.Tew, J. G., Kosko, M. H., Burton, G. F., & Szakal, A. K.Follicular dendritic cells as accessory cells, Immunological Reviews, 1990, 117, 185–212.CrossRefGoogle ScholarPubMed